Cannabis Law Report

NOVEMBER 4, 2021

Drug Enforcement Agency (DEA) to cultivate marijuana for research purposes. In 2016, Dr. Sue Sisley first applied to grow cannabis for research purposes when the Obama administration announced a plan to allow other growers to provide cannabis to researchers. Use the plants for their own studies and/or FDA clinical trials.

DEA 52

DEA Clinical Trials Advocacy Legislation 52

Cannabis Law Report

JUNE 3, 2021

A Seattle palliative care physician has filed a lawsuit against the DEA, contesting its decision to ban psilocybin for use by terminally ill patients.

DEA 98

DEA Access Clinical Trials Patients 98

Cannabis Law Report

APRIL 12, 2022

Attorneys representing a cannabis biopharma conglomerate and federal cannabis cultivation license applicant filed a petition in court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application. . Breaking Exclusive: Another Cannabis Company Sues the DEA.

DEA 52

DEA Cultivation Clinical Trials Cannabis 52

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

Cannabis Law Report

MARCH 30, 2022

Legislation unanimously passed by members of the US Senate empowers the US Attorney General to facilitate clinical research trials involving cannabis. NORML write. The action represents one of the very few occasions that members of the Senate have ever advanced a marijuana-related reform bill.

Legislation 95

Legislation Clinical Trials DEA Access 95

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 66

DEA Clinical Trials THC Research and Development 66

NORML

MARCH 1, 2019

Currently, the sole federally licensed producer of cannabis for clinical research is the University of Mississippi. ” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. .”

DEA 173

DEA Research and Development Clinical Trials Marijuana 173

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

SEPTEMBER 4, 2021

Much of the argument, before Circuit Judges Mark Bennett, Sandra Ikuta and Ryan Nelson, focused on whether the DEA’s conclusion that it could not waive any part of the federal Controlled Substances Act (CSA), which bans psilocybin except for limited research purposes, could even be appealed. Forty-one states have passed such laws.

Clinical Trials 109

Clinical Trials Law DEA Patients 109

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

SpeedWeed

JULY 23, 2021

This is the first time a research license for this type of work has been granted outside of state and city research licenses to study cannabis. . Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

NewsMunchies

NOVEMBER 12, 2021

As the cannabis industry continues to grow and evolve with legalization achieved in many parts of the world, we’re seeing an increase in activity related to another substance that will hopefully be removed from the list of controlled substances – psilocybin. Additional clinical trials underway in the U.S.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

SpeedWeed

AUGUST 11, 2021

MAPS, The Multidisciplinary Association for Psychedelic Substances, was awarded a $12,979,050 million grant from the state of Michigan to fund a study on PTSD and cannabis on August 10. This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Though, Oregon is actively in the process of establishing a model for psilocybin that would be like the state’s current medical cannabis system. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. This is a policy where the federal government, the DEA, will refrain from taking prosecutorial action if state law permits, regulates, and carefully controls the use of a drug.

Therapy 52

Therapy Patients Law Clinical Trials 52

SpeedWeed

AUGUST 16, 2021

LAS VEGAS, NV [August 16, 2021] – Cannabis Conference , produced by parent company GIE Media Inc. Dr. Sisley will highlight cutting-edge discoveries from her roles in cannabis studies for pain management and post-traumatic stress disorder (PTSD), as a substitution therapy for opioids, and more. 25 from 11 a.m. –

Media 52

Media Clinical Trials DEA Hemp 52

Cannabis Law Report

MARCH 18, 2022

Similar to the early days of the medical cannabis movement, psychedelic drugs such as MDMA, psilocybin, LSD, ketamine and DMT are being developed for therapeutic use in a complex and difficult legal and regulatory environment. The firm’s multidisciplinary team covers commercial, regulatory and legal requirements spanning U.S. Steve Levine.

Therapy 52

Therapy Research and Development Clinical Trials Environment 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

SEPTEMBER 20, 2019

The sale will greatly reduce the current and future burn rate of the company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the U.S.

Clinical Trials 40

Clinical Trials Research and Development DEA Business 40

MedicalJane

JUNE 29, 2018

None of the approved drugs contain, or are derived from, the whole cannabis plant. a Canada-based medical cannabis firm. “It rapidly destigmatizes what cannabis can do.” Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

OCTOBER 5, 2021

The drug has previously been used with some success in clinical trials designed to treat depression. These trials typically involve the use of music playlists to support the psychedelic experience.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

JULY 9, 2021

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105

NORML

DECEMBER 9, 2020

The reality that most high-schoolers have easier access to cannabis than do our nation’s top scientists is the height of absurdity and an indictment of the current system.”. “These common-sense regulatory changes are necessary and long overdue.

Access 246

Access Marijuana Clinical Trials Cannabis 246

Canna Law Blog

JANUARY 3, 2023

Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”). The future of FDA CBD regulations.

CBD 75

CBD Food Clinical Trials Pets 75

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. One group self-administered cannabis with 12% THC over three weeks.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

MARCH 2, 2020

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). The rollercoaster starts here!

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

SpeedWeed

MARCH 25, 2021

A long-awaited clinical trial on using cannabis as a treatment for veterans with PTSD has finally been published in the PLOS One journal , but the results are far less promising than researchers and veterans had hoped. grams of cannabis flower or a placebo every day for 3 weeks. Each subject was asked to smoke 1.8

DEA 52

DEA Clinical Trials THC Pharmaceutical 52

CannaMD

AUGUST 8, 2020

– because today’s post is a deep dive into everything you need to know about the most popular cannabis compound around. Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol. Researchers believe cannabis contains over 100 unique chemical compounds!

CBD 100

CBD DEA Research and Development Hemp 100

Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

APRIL 1, 2019

Selling dried cannabis to pharmaceutical companies as well as Cannabidiol (CBD) and Tetrahydrocannabinol (THC) extracts as soon as it is licensed, is the intention of Thailand’s tobacco authority among new measures to turn a profit on its dwindling cigarette business. TOAT, the First Thai Cannabis Money Maker.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 15 × 15. 16 × 16.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

SpeedWeed

MARCH 5, 2021

Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. Bilmoria opine: “[R]emoving cannabis from Schedule I of the CSA would mean that it could be treated as any other physician-prescribed drug. Authors Tracy Gallegos and Neville M.

Business 52

Business Policy Clinical Trials Research and Development 52

Cannabis Law Report

AUGUST 18, 2022

Study and development of these treatments remain challenging as psilocybin, MDMA, DMT and LSD are all listed as DEA Schedule I drugs. Building on its work in the life sciences, cannabis and other innovative technologies, this latest entry into an emerging legal field marks another milestone for Phillips Lytle.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

NORML

APRIL 8, 2020

The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.

Cultivation 356

Cultivation DEA Clinical Trials Marijuana 356